Access Official Technical PDF

Share Summary:LinkedInEmail

Bio-CMO manufacturing brings together specialized facilities, process knowledge and quality systems to produce biologic medicines for pharmaceutical companies. Samsung BioLogics’ 2016 annual report offers a useful historical view of the operating demands behind this model: customers outsource production to access manufacturing capabilities without taking on the full investment and operational burden of building and running their own facilities.

For automation engineers, system integrators and operations leaders, the report highlights a central point: biologics manufacturing is not simply a matter of adding production volume. Successful execution depends on transferring a customer’s process, controlling a complex sequence of operations and demonstrating that the facility and product meet applicable regulatory and quality requirements.

Why pharmaceutical companies use bio-CMO manufacturing

Biologics are medicines made using living cells, including therapeutic proteins produced through gene recombination and cell culture. Compared with conventional synthetic drugs, their production involves more complex processes and specialized equipment. The report describes antibody drug manufacturing as dependent on mammalian cells and on careful control across cell culture, purification and filling.

Building a facility for commercial biologics production requires substantial investment and a long preparation period. A pharmaceutical company considering a new medicine may face uncertainty about whether the product will receive marketing authorization and what demand will be. Contract manufacturing can provide access to production services while allowing the customer to focus its investment and attention on other activities, including research and development or marketing.

Outsourcing also supports production planning. The report identifies the use of multiple manufacturing sources as one way companies seek supply stability. In this model, a CMO’s production capacity, quality systems and ability to meet customer requirements become important considerations in supplier selection.

Technology transfer turns a customer process into a production process

A CMO does not simply apply a generic recipe to every product. The customer transfers its manufacturing technology, and the CMO works to reproduce the customer’s process within its own facility. The aim is to minimize differences between the original process and the one used for outsourced production.

That transfer is followed by production runs designed to demonstrate process performance and consistency. The report describes engineering runs and process validation runs as steps taken before seeking regulatory approval for the product and manufacturing process. The work requires coordination between customer and manufacturer, as well as documentation of procedures and results.

A typical sequence for an antibody drug includes:

  • Upstream processing: Customer-provided cells are scaled up and cultured to produce the target protein.
  • Collection and downstream processing: The harvested material is processed, with chromatography and filtration used to remove impurities and increase protein purity.
  • Fill and finish: The product is filled, packed and labelled under controlled aseptic conditions.

Each stage has process requirements that must be maintained across production. The report notes that customers may inspect the overall manufacturing process and request necessary measures. Manufacturing records also support review by customers and regulators.

GMP and facility readiness are core operational requirements

Good Manufacturing Practice (GMP) is central to producing medicines consistently under controlled conditions. For a biologics CMO, compliance is not limited to a final product check: it applies across the manufacturing process and its supporting systems. Regulatory authorities assess manufacturing processes and quality controls, including through inspections of new facilities, before granting relevant manufacturing approvals.

Facility readiness therefore involves more than construction. Equipment and processes must be verified, production methods must be established, and the manufacturer must demonstrate that it can meet the required standards. In its 2016 report, Samsung BioLogics stated that Plant #1 had received manufacturing license approvals from the FDA and EMA. The report also described Plant #2 as having completed construction and facility verification in February 2016, with commercial production expected to begin.

These details illustrate why qualification and regulatory preparation form part of the production timeline. The report said customers typically needed more than two years to prepare for commercial production through a CMO, including technology transfer, pilot production and compliance with the requirements of different regulators. It also described long-term contracts as common in the sector.

Capacity planning must account for the process, not just vessel volume

Large-scale capacity can help a CMO serve customer programs, but nominal facility capacity does not translate directly into a fixed volume of finished product. The report explains that production capacity can vary with production intervals, success rates and the number of products made per batch. It calculated capacity using working days, production cycle time and a reserve allowance.

For 2016, the report listed Samsung BioLogics’ installed capacity as 182,000 liters across Plant #1 and Plant #2, while Plant #3 was under construction. Its stated production performance was 152 batches, against a standard capacity of 220 batches for the year. The report noted that Plant #2 began manufacturing in April, affecting the capacity available during that year. These are historical figures, but they show why operational assessments should distinguish installed capacity, available capacity and actual production performance.

Planning also depends on customer demand and materials. The report describes customers as supplying or designating suppliers for certain raw materials, with the manufacturer arranging supply accordingly. Long-term supplier agreements were used to support continuity. Contract terms, minimum production volumes and reserved capacity also shape how a facility allocates resources.

Practical implications for automation and operations teams

For teams designing or operating biologics facilities, the report’s account underscores the close relationship between automation, process execution and quality documentation. Equipment and controls must support repeatable operations, while records need to make process activities and results traceable for customer and regulatory review. Technology transfer and validation should be treated as coordinated operational programs, not isolated commissioning tasks.

Capacity decisions should likewise be grounded in the full production cycle. Cell culture, purification and aseptic filling each contribute to scheduling and resource requirements. A facility’s headline volume is only one part of the picture; batch performance, process duration, planned maintenance and customer-specific requirements also matter.

Conclusion

Bio-CMO manufacturing is built on the combination of specialized production assets, disciplined process transfer and rigorous GMP controls. The 2016 example shows how commercial readiness depends on demonstrating that a customer’s process can be reproduced and operated under controlled conditions—not simply on constructing additional capacity. For technical decision-makers, that means evaluating CMOs and facility plans through the full lifecycle: transfer, validation, production, documentation and supply planning.

Access Official Technical PDF

About The Author